Outcome Terapi Covid-19 pada Pasien yang Mendapatkan Antikoagulan Profilaksis di RSPAL Dr. Ramelan Surabaya: Outcome Covid-19 Anticoagulant Prophylaxis in Covid-19 Patients at Dr. Ramelan Naval Center Hospital Surabaya

Rizki Damayanti (Universitas Surabaya)
Anita Purnamayanti (Universitas Surabaya)
Aguslina Kirtishanti (Universitas Surabaya)
Ediyono Ediyono (Rumah Sakit Pusat TNI Angkatan Laut Dr. Ramelan Surabaya)

Jurnal Surya Medika
Vol. 8 No. 3 (2022): Jurnal Surya Medika (JSM)

Complications of thrombotic and hemorrhagic coagulation often occur in Covid-19 patients, so it is advisable to provide anticoagulant therapy, accompanied by monitoring of parameters of coagulation abnormalities, including D-Dimer. This study aims to determine the outcome of therapy for Covid-19 in patients with anticoagulant prophylaxis use in RSPAL Dr. Ramelan Surabaya. This study is a retrospective descriptive study based on medical records of Covid-19 patients from June-August 2021. The sample in this study was subjects aged >18 years who were confirmed positive for Covid-19 based on RT-PCR, with comorbid or without comorbidities, and received anticoagulant therapy. Then, this study did not include subjects who were pregnant or with malignancy/acute conditions. From 134 research samples, it was found that the use of anticoagulants using a single anticoagulant (n=131, 97.76%) was more widely used, with the most frequently used types being enoxaparin (n=68, 50.75%), and heparin (n=48, 35,8%). In conclusion, the recovery percentage in Covid-19 subjects with anticoagulant therapy was 77.61%, and the percentage of mortality was 22,39%.